AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions (2022)
Attributed to:
Biology and Treatment of Human Myeloid Cancers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01257-5
Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138157209
Type: Journal Article/Review
Parent Publication: Clinical Lymphoma Myeloma and Leukemia